Nuzenio

Tradingview Biocryst Pharmaceuticals

Tradingview Biocryst Pharmaceuticals entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 8 latest news signals 1 publisher sources 100/100 entity strength

Latest news

BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside - TradingViewTradingView · Wed, 05 Aug 2026 21:20:08 GMTBCRX: Q2 revenue up 45% year-over-year, with robust ORLADEYO growth and strong cash position - TradingViewTradingView · Wed, 05 Aug 2026 14:14:05 GMTBioCryst Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Wed, 05 Aug 2026 14:04:29 GMTBioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Wed, 05 Aug 2026 13:31:59 GMTBiocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026 - TradingViewTradingView · Wed, 05 Aug 2026 12:18:02 GMTBCRX: Q2 2026 delivered robust revenue and profit growth, with raised guidance and pipeline progress - TradingViewTradingView · Wed, 05 Aug 2026 11:25:16 GMTBCRX: Q2 2026 delivered robust revenue and profit growth, with a strong outlook for the HAE franchise - TradingViewTradingView · Wed, 05 Aug 2026 11:06:37 GMTBCRX Q2'26 Earnings: EPS estimate is 0.15 USD - TradingViewTradingView · Tue, 04 Aug 2026 11:01:01 GMT

Timeline

Wed, 05 Aug 2026 21:20:08 GMTBioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside - TradingView
Wed, 05 Aug 2026 14:14:05 GMTBCRX: Q2 revenue up 45% year-over-year, with robust ORLADEYO growth and strong cash position - TradingView
Wed, 05 Aug 2026 14:04:29 GMTBioCryst Pharmaceuticals Q2 Earnings Call Highlights - TradingView
Wed, 05 Aug 2026 13:31:59 GMTBioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView
Wed, 05 Aug 2026 12:18:02 GMTBiocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026 - TradingView
Wed, 05 Aug 2026 11:25:16 GMTBCRX: Q2 2026 delivered robust revenue and profit growth, with raised guidance and pipeline progress - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Biocryst Pharmaceuticals.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.